Curium Pharma

What Curium Pharma does

Curium Pharma, founded in 2017 and privately held by CapVest Partners LLP, is a vertically-integrated nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals to hospitals, radiopharmacies, and imaging centers across 60-70 countries, serving approximately 14 million patients annually. The company operates the industry's largest vertically-integrated radiopharmaceutical manufacturing network, comprising four main production sites (Maryland Heights and Noblesville in the United States, Petten in the Netherlands, and Saclay in France), a captive molybdenum-99 processing facility, multiple cyclotrons, and 44-45+ PET and SPECT radiopharmacies across the US and Europe. Its portfolio of 50+ products spans Mo-99/Tc-99m generators (Ultra-Technekow), cold kits (DTPA), ready-to-administer PET and SPECT imaging agents (PYLCLARI, Striascan), and therapeutic radiopharmaceuticals (Quadramet, Radiosynoviorthese products), with key growth assets including the Phase 3 ECLIPSE program for Lu-177 zadavotide guraxetan in metastatic castration-resistant prostate cancer, Lu-177 dotatate for GEP-NETs (cleared for US launch after a June 2026 patent victory against Novartis/AAA), and the Curium Biopharma discovery unit launched in November 2025.

The company employs 5,000+ staff globally and goes to market through a direct enterprise sales force (25+ personnel in North America, 70+ across Europe and rest of world), country-specific sales offices in 15+ markets, and 44+ nuclear pharmacies that provide localized distribution of short-half-life isotopes. Curium's revenue is generated primarily through one-time B2B product sales of radiopharmaceuticals to healthcare providers; pricing is not publicly disclosed. The business model is reinforced by strategic alliances with PeptiDream, PDRadiopharma (for 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan), Curasight, and NRG PALLAS for isotope supply, and by recent acquisitions of Monrol (Lutetium-177 capacity) and Nucleis (European PET capacity) completed in March and April 2025. With a global headquarters established in Boston in November 2025 alongside the historical Paris European headquarters, and a $7 billion CapVest recapitalization completed in Q1 2026, Curium is positioned as a scaled, profitable platform pursuing theranostic and geographic expansion into the United States, China, and Japan.

Name

Curium Pharma

Legal name

Curium Group sarl

Website

https://www.curiumpharma.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Curium Pharma is a vertically-integrated nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals to hospitals, radiopharmacies, and imaging centers across 60-70 countries, serving 14 million patients annually with 50+ products through four manufacturing sites and 44+ radiopharmacies.

Ownership category

akta.pro rank

Product category

Nuclear Medicine / Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Irradiation Apparatus Manufacturing (334517)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE)

Keywords

• Nuclear medicine solutions
• Radiopharmaceutical manufacturing
• PET imaging agents
• SPECT radiopharmaceuticals
• Radioligand therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices24 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Radiopharmaceutical Products: Sale of diagnostic and therapeutic radiopharmaceutical products including generators (Tc-99m), cold kits, hot products, and auxiliary products used in diagnosis and treatment of thyroid, lungs, liver, bones, brain, heart, glands, kidneys and joints diseases.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Curium Pharma manufactures and distributes a portfolio of 50+ radiopharmaceutical products used in nuclear medicine diagnosis and therapy. Its core offerings include Molybdenum-99/Technetium-99m generators, cold kits for radiopharmaceutical preparation, ready-to-administer PET and SPECT imaging agents, and therapeutic radioligands such as Lutetium-177-based products for cancer treatment. The company serves hospitals, radiopharmacies, and imaging centers across more than 60 countries.

Product overview

Curium Pharma is the world's leading nuclear medicine company offering a diverse portfolio of over 50 radiopharmaceutical products. The portfolio includes Mo-99/Tc-99m generators (Ultra-Technekow™), cold kits, hot products (ready-to-administer PET and SPECT imaging agents), and auxiliary products used for diagnosis and treatment of cancers affecting thyroid, lungs, liver, bones, brain, heart, glands, kidneys and joints. Key commercial products include PYLCLARI® (18F-PSMA PET tracer for prostate cancer), DTPA injection, Striascan™, Quadramet®, and radiosynoviorthese products. The pipeline includes investigational Lutetium-177 Zadavotide Guraxetan (Phase 3 ECLIPSE trial for prostate cancer), 177Lu-PSMA-I&T, and 64Cu-PSMA-I&T in clinical development. The November 2025 launch of Curium Biopharma created a dedicated business unit for discovery and product development. Products are manufactured across four main production sites (Maryland Heights, Missouri; Noblesville, Indiana; Petten, Netherlands; Saclay, France) and distributed through 44+ PET and SPECT radiopharmacies across the US and Europe.

Differentiator

Problem solved

Functional benefit

Products and services

• Generators (Mo-99/Tc-99m)
• Cold Kits
• Hot Products (PET and SPECT Imaging Agents)
• Auxiliary Products
• PYLCLARI® (18F-PSMA PET Tracer)
• Ultra-Technekow™ (99Mo/99mTc Generator)
• DTPA (Kit for Preparation of Technetium Tc 99m Pentetate Injection)
• Striascan™
• Quadramet®
• Radiosynoviorthese Products (RSO)
• DetectNet
• Lu-177 Zadavotide Guraxetan
• 177Lu-PSMA-I&T
• 64Cu-PSMA-I&T
• Lutetium Lu 177 Dotatate
• AlphaMedix
• Curium Biopharma (Business Unit)

Quantifiable outcome

• Serves 14 million patients annually
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• PeptiDream Inc.coreStrategic or Co-development Partner · 4 February 2026Curium Group partnered with PeptiDream Inc. and PDRadiopharma Inc. for a registrational Phase 2 clinical trial in Japan for 177Lu-PSMA-I&T, a Lutetium-177 radiotherapeutic agent targeting PSMA-positive metastatic castration-resistant prostate cancer. PDRadiopharma leads regulatory filing, manufacturing, and commercialization in Japan.
• PDRadiopharma Inc.coreStrategic or Co-development Partner · 4 February 2026In partnership with Curium Group and PeptiDream Inc., PDRadiopharma leads regulatory filing, manufacturing, and commercialization of 177Lu-PSMA-I&T for prostate cancer in Japan. The companies enrolled first patient in February 2026.
• NucleiscoreStrategic or Co-development Partner · 10 April 2025Curium enhanced its PET manufacturing capacity and expanded European footprint with the acquisition of Nucleis, strengthening production capabilities in Europe.
• MonrolcoreStrategic or Co-development Partner · 28 March 2025Curium completed the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint, enhancing manufacturing capabilities for therapeutic radiopharmaceuticals.
• IzotopminorStrategic or Co-development Partner · 30 January 2025Curium expanded European supply of Iodine-131 diagnostic capsules with new partnership agreement with Izotop, broadening product portfolio and geographic coverage.
• Curasight A/ScoreStrategic or Co-development PartnerCurium is collaborating with Curasight A/S on a Phase 3 trial. Curasight secured financing of DKK 16.4 million through directed share issue and DKK 40 million loan facility to fund clinical development programs including Phase 1 and Phase 2 trials for uTREAT in brain cancer and uTRACE in prostate cancer, with Phase 3 trial in collaboration with Curium.
• Curasight A/ScoreStrategic or Co-development PartnerCurasight's financing will fund clinical development including a Phase 3 trial in collaboration with Curium, expected to sustain operations through end of 2026. The partnership focuses on uTREAT in brain cancer and uTRACE in prostate cancer.
• NRG PALLAScoreStrategic or Co-development PartnerCurium and NRG PALLAS extended their collaboration in the supply of essential medical isotope to hospitals, strengthening the supply chain for critical radiopharmaceuticals.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Lantheus Holdings: US specialty radiopharmaceutical company and direct competitor in PSMA PET imaging (Pylarify) and diagnostic radiopharmaceuticals. Comparable as a vertically-integrated radiopharma operator with similar therapeutic/diagnostic portfolio mix and customer base of hospitals and imaging centers.
• Novartis (AAA / Advanced Accelerator Applications): Owner of Lutathera (Lu-177 dotatate) and Pluvicto (Lu-177 vipivotide) — the dominant Lu-177 therapeutic franchise. Direct competitor in targeted radioligand therapy for GEP-NETs and mCRPC, against whom Curium just won its Lu-177 dotatate patent dispute.
• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing PSMA-targeted imaging (Illuccix) and therapeutic agents. Direct competitor in prostate cancer imaging and emerging player in Lu-177 therapeutics, with comparable hospital/imaging center GTM motion.
• Cardinal Health (Nuclear Pharmacy Services): Operates the largest US nuclear pharmacy network distributing radiopharmaceuticals to hospitals. Directly comparable as a B2B distributor and nuclear pharmacy operator serving the same hospital/imaging center customer base, though Cardinal is broader (medical distribution).
• Siemens Healthineers (PETNET Solutions): Operates PETNET Solutions, a global network of PET radiopharmacies producing and distributing F-18 and other PET tracers. Directly competes with Curium's 44 nuclear pharmacies in PET imaging agent distribution to hospitals and imaging centers.
• Bracco Imaging: Privately-held Italian imaging agent company with diagnostic imaging and radiopharmaceutical portfolio including Blue Earth Diagnostics (acquired). Overlaps with Curium in contrast agents, nuclear medicine imaging, and PSMA imaging through Posluma.
• Eckert & Ziegler: German-based specialist in radioisotopes, radiation sources, and radiopharmaceutical services including FDG production. Comparable as a vertically-integrated radiopharma and isotope manufacturer serving hospital and industrial customers across Europe and globally.
• Ion Beam Applications (IBA): Belgian company manufacturing cyclotrons, radiopharmaceuticals, and particle therapy systems. Direct comparable in radiopharma manufacturing and PET tracer production; Curium's Chief Legal Officer previously served 15 years as CLO at IBA, evidencing close industry knowledge overlap.

Broad incumbents

• Bayer (Radiology / Xofigo): Large pharma with radiopharmaceutical franchise including Xofigo (Ra-223 for bone metastases) and broader oncology/radiology portfolio. Overlaps with Curium in therapeutic radiopharma and nuclear medicine services, though Bayer's radiopharma is one segment of a diversified life sciences company.
• GE HealthCare: Global medical imaging and diagnostics incumbent with a radiopharmaceutical product portfolio and PET tracer manufacturing. Overlaps with Curium in SPECT/PET imaging agents and nuclear medicine services, though within a much broader imaging hardware and software portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCehf34Bp449GjKFowrpyBKg
• LinkedInlinkedin.com/company/curiumpharma
• Instagraminstagram.com/curium_pharma
• Xx.com/curium_pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curium Pharma